GSK Adds £50m Per Year To Brexit Cost Estimates
Brexit is likely to cost GSK around £50m a year in the form of customs duties and transaction and administration costs. It is one of a handful of companies to have made its cost estimates public.
You may also be interested in...
Pharmaceutical executives from GSK, Sanofi and the UK generic medicines industry body giving evidence on the likely effects of Brexit on the UK life sciences sector at a recent parliamentary committee hearing were asked why they have not been more outspoken about their concerns.
The UK pharmaceutical industry has welcomed the announcement that Brexit talks are to move on to trade deal discussions, but says a regulatory cooperation agreement and a fixed transition period are essential to safeguard European supply chains. Several pharma executives outlined some of their key concerns at a parliamentary committee hearing on Dec. 5.
Valneva is scaling up manufacture of its coronavirus vaccine alongside the clinical development program, with a view to meeting its commitment to provide millions of doses for use in the UK and the EU.